Reaktionsgleichung
Cl[C:2]1[C:3]([N:7]2[CH2:12][CH:11]([CH3:13])[NH:10][CH:9]([CH3:14])[CH2:8]2)=[N:4][S:5][N:6]=1.[N:15]1[CH:20]=[CH:19][CH:18]=[CH:17][C:16]=1CO.C([CH:27](CCC)[O-:28])(C)(C)C.[K+].C(O)(C)(C)C>O>[CH3:14][CH:9]1[NH:10][CH:11]([CH3:13])[CH2:12][N:7]([C:3]2[C:2]([O:28][CH2:27][C:18]3[CH:17]=[CH:16][N:15]=[CH:20][CH:19]=3)=[N:6][S:5][N:4]=2)[CH2:8]1Komponenten
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
1-(4-Chloro-[1,2,5]thiadiazol-3-yl)-3,5-dimethyl-piperazine (7.9 g, 34 mmol), pyridinyl-methanol (7.7 g, 70 mmol), potassium tert-butyl butoxide (11.4 g, 101 mmol) and tert-butyl alcohol (100 mL) were combined and stirred at room temperature overnight. The reaction mixture is diluted with H2O (3×) and extracted with EtOAc (3×). The combined EtOAc extractions are washed with sat'd NaHCO3 (3×), sat'd NaCl (1×), dried (Na2SO4), and concentrated in vacuo. The crude product is purified by column chromatography (1:1 hexanes:EtOAc, followed by 49:1 EtOAc:triethylamine, followed by 18:1:1 EtOAc:MeOH:triethylamine) to give 4.15 g (40%) of 3,5-dimethyl-1-[4-(pyridin-4-ylmethoxy)-[1,2,5]thiadiazol-3-yl]-piperazine. 1H NMR (CDCl3) 8.62 (d, 2H), 7.30 (d, 2H), 5.48 (s, 2H), 4.07 (m, 2H), 3.03 (m, 2H), 2.51 (m, 2H), 1.12 (d, 6H) ppm. LC-MS (MH+)=306.
Aufarbeitung
- extractionextracted with EtOAc (3×)
- extractionThe combined EtOAc extractions
- washare washed with sat'd NaHCO3 (3×), sat'd NaCl (1×)
- dry with materialdried (Na2SO4)
- concentrationconcentrated in vacuo
- customThe crude product is purified by column chromatography (1:1 hexanes:EtOAc, followed by 49:1 EtOAc:triethylamine, followed by 18:1:1 EtOAc:MeOH:triethylamine)
Quellen und Nachweise
- ORD-Eintrag
- ord-52f9bd47c74a4486ae169fbcb74c2a81
- Quelldatensatz
- uspto-grants-2011_09
- Patentnummer
- US08013156B2
Verknüpfte Notizen
Wird geladen…